Allena Pharmaceuticals, Inc. (ALNA): Price and Financial Metrics


Allena Pharmaceuticals, Inc. (ALNA): $0.21

0.02 (+10.99%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ALNA Stock Price Chart Interactive Chart >

Price chart for ALNA

ALNA Price/Volume Stats

Current price $0.21 52-week high $1.45
Prev. close $0.19 52-week low $0.07
Day low $0.21 Volume 188,264,000
Day high $0.33 Avg. volume 13,369,978
50-day MA $0.14 Dividend yield N/A
200-day MA $0.48 Market Cap 22.84M

Allena Pharmaceuticals, Inc. (ALNA) Company Bio


Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company’s lead product candidate includes ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It is also involved in developing ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is based in Newton, Massachusetts.


ALNA Latest News Stream


Event/Time News Detail
Loading, please wait...

ALNA Latest Social Stream


Loading social stream, please wait...

View Full ALNA Social Stream

Latest ALNA News From Around the Web

Below are the latest news stories about Allena Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALNA as an investment opportunity.

Allena Pharmaceuticals: A Double [Or More] Or Kaput In The Next 90 Days

No summary available.

Seeking Alpha | January 7, 2022

Analysts’ Top Healthcare Picks: Allena Pharmaceuticals (ALNA), Unity Biotechnology (UBX)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Allena Pharmaceuticals (ALNA – Research Report) and Unity Biotechnology (UBX – Research Report) with bullish sentiments. Allena Pharmaceuticals (ALNA) Wedbush analyst Liana Moussatos reiterated a Buy rating on Allena Pharmaceuticals today and set a price target of $4.00. The company's shares closed last Tuesday at $0.58. According to TipRanks.

Howard Kim on TipRanks | January 5, 2022

Allena Pharmaceuticals (ALNA) Receives a Buy from B.Riley Financial

B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Allena Pharmaceuticals (ALNA – Research Report) today and set a price target of $4.00. The company's shares closed last Wednesday at $0.51. According to TipRanks.com, Mamtani is a 1-star analyst with an average return of -0.2% and a 36.6% success rate. Mamtani covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Madrigal Pharmaceuticals, and Spectrum Pharmaceuticals. Allena Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $6.33, which is a 1052.2% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $11.

Brian Anderson on TipRanks | January 5, 2022

Analysts Offer Insights on Healthcare Companies: Oncternal Therapeutics (ONCT), Allena Pharmaceuticals (ALNA) and Gritstone Oncology (GRTS)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Oncternal Therapeutics (ONCT – Research Report), Allena Pharmaceuticals (ALNA – Research Report) and Gritstone Oncology (GRTS – Research Report) with bullish sentiments. Oncternal Therapeutics (ONCT) H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Oncternal Therapeutics today and set a price target of $9.00. The company's shares closed last Tuesday at $2.34. According to TipRanks.

Christine Brown on TipRanks | January 5, 2022

Allena Pharmaceuticals Provides Clinical and Corporate Update

ALLN-346, an orally administered enzyme in development for the treatment of hyperuricemia and gout, demonstrates a statistically significant reduction in serum uric acid and a well-tolerated safety profile in first cohort of patients with hyperuricemia and chronic kidney disease in the Phase 2a Study 201 Allena to host webinar to discuss the initial Study 201 data with Key Opinion Leaders Robert Terkeltaub, M.D. and David S. Goldfarb, M.D. today at 8:00 am ET; log-in information belowALLN-346 Ph

Yahoo | January 4, 2022

Read More 'ALNA' Stories Here

ALNA Price Returns

1-mo 86.67%
3-mo -13.04%
6-mo -63.74%
1-year -84.09%
3-year -95.81%
5-year N/A
YTD -64.56%
2021 -53.71%
2020 -53.11%
2019 -49.91%
2018 -45.83%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4596 seconds.